P2.10-10 Co-occurring Loss of CDKN2A/2B Associated with Worse Survival and Increase Risk of Brain Metastasis in ALK-Rearranged Non-small Cell Lung Cancer

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have demonstrated promising activity in ALK-rearranged non-small cell lung cancer (NSCLC). Co-occurring genetic alterations might impact the efficacy of target therapies, especially those downstream tumor initiation oncogenes. This study analyzed whether co-occurring alterations impact survival outcomes of metastatic ALK-rearranged NSCLC who received second-generation ALK-TKIs.